Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.